Because Bozo berman is the CEO of DECN and has done nothing but lose money tear over year with scheme after scheme.
Recent ESPR News
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/14/2026 08:30:00 PM
- Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 • GlobeNewswire Inc. • 05/13/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:10:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/04/2026 08:05:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/01/2026 08:00:21 PM
- Esperion to be Acquired by ARCHIMED • GlobeNewswire Inc. • 05/01/2026 11:00:00 AM
- Esperion to Report First Quarter 2026 Financial Results on May 7 • GlobeNewswire Inc. • 04/23/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2026 08:12:55 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 08:11:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:22:14 PM
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) • GlobeNewswire Inc. • 04/02/2026 08:00:00 PM
- Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:12:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:19:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:17:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:12:41 PM
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session • GlobeNewswire Inc. • 03/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 08:20:52 PM
- Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia • GlobeNewswire Inc. • 03/16/2026 10:30:00 AM
- Esperion shares rise 8% after revenue tops forecasts and acquisition announced • IH Market News • 03/10/2026 12:56:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 11:17:29 AM
